- Home
- CMMB
as 07-26-2024 4:00pm EST
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
| Founded: | 2004 | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | 15.8M | IPO Year: | N/A |
| Target Price: | $5.67 | AVG Volume (30 days): | 217.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.42 - $1.58 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Chemomab Therapeutics Ltd. News
CMMB Breaking Stock News: Dive into CMMB Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 hours ago
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
GlobeNewswire
2 days ago
Chemomab Therapeutics Announces $10 Million Private Placement
GlobeNewswire
2 days ago
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
GlobeNewswire
a month ago
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
GlobeNewswire
2 months ago
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
GlobeNewswire
2 months ago
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
GlobeNewswire
3 months ago
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
3 months ago
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Compare CMMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CMMB Chemomab Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.